Ryan Haumschild, PharmD, MS, MBA, director of pharmacy services at Emory Healthcare and Winship Cancer Institute, tackles how stakeholders can collaborate and utilize market data to effectively boost biosimilar uptake.
Ryan Haumschild, PharmD, MS, MBA, director of pharmacy services at Emory Healthcare and Winship Cancer Institute, tackles how stakeholders can collaborate and utilize market data to effectively boost biosimilar uptake.
Transcript
How can different stakeholders work together to ensure improved biosimilar utilization across disease states?
Haumschild: I think that’s one of the things that we want to continue to expand upon. How do we get good biosimilar use in oncology, but then good biosimilar use in the immunology disease states, such as rheumatology and gastroenterology? And believe it or not, there’s different uptakes between the different disease states. If we’re using biosimilars and we’re extrapolating data to treat patients in the curative intent, how can we not extrapolate data from gastroenterology to rheumatology, and then start to look at interchangeability?
There’s going to be a never-ending appetite for data, and that’s okay because we’re data driven. How can we leverage the experiences we’ve had and the similar outcomes between reference projects and biologics, and move that into the biosimilar space, so that we can make more timely approvals? Not just wait for every single study and every single patient. And also look at switching immunogenicity and feel comfortable moving forward biosimilars across the board.
IQVIA Highlights Opportunity to Cash In on Biosimilars for Biologics Losing Market Exclusivity
November 29th 2023A report from IQVIA noted that Europe could miss out on €15 billion in cost savings by not having biosimilars for medications about to lose market exclusivity, shedding light on the implications for overall health care savings and ultimately, patient access.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
November 16th 2023In part 3 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® reviews an analysis investigating whether clinical efficacy studies have an impact on prescribing decisions for oncology biosimilars across Europe.
Panelists Deliberate Strategies to Enhance Biosimilar Integration in Managed Care Spaces
November 13th 2023At the recent Academy of Managed Care Pharmacy Nexus meeting, panelists discussed the impact of introducing biosimilars in new medical fields, emphasizing the need for more education and collaboration to ensure their smooth integration into health care systems.